With the global expansion of coronavirus disease 2019 (COVID-19) and the declaration of its outbreak as a Public Health Emergency of International Concern by the World Health Organization, there is an urgent need for vaccines and medicines to prevent and treat COVID-19. The responsible pathogen for the disease is the newly severe acute respiratory syndrome coronavirus (SARS-CoV) 2 belonging to the same family of viruses SARS-CoV and Middle East respiratory syndrome coronavirus that originally are zoonotic and have been associated with severe illness during the outbreaks in 2003 and 2012, respectively. The virulence of coronavirus strains is mainly associated with variations in surface proteins mediating cellular entry of the virus, which can help in finding effective therapeutic targets. In this review, we seek evidence showing the role of coronavirus spike protein (S-protein) and its potential cellular receptor, angiotensin-converting enzyme 2 (ACE2), during infection of coronaviruses, including the newly SARS-CoV-2 and its similar strain SARS-CoV. This review also discusses the therapeutic effect of inhibiting the renin–angiotensin system cascade, a target of ACE2, in patients having coronavirus with cardiovascular disease.
FehrARPerlmanS. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
2.
LiF. Structure, function, and evolution of coronavirus spike proteins. Ann Rev Virol. 2016;3:237–61.
3.
KuoLGodekeGJRaamsmanMJMastersPSRottierPJ. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J Virol. 2000;74:1393–406.
4.
PhillipsJJChuaMMLaviEWeissSR. Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence. J Virol. 1999;73:7752–60.
5.
WongSKLiWMooreMJChoeHFarzanM. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004;279:3197–201.
6.
HoffmannMKleine-WeberHSchroederS, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
7.
ZhangHPenningerJMLiYZhongNSlutskyAS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Int Care Med. 2020;46:586–90.
8.
SuSWongGShiW, et al.Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trend Microbiol. 2016;24:490–502.
9.
XiaoXChakrabortiSDimitrovASGramatikoffKDimitrovDS. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Comm. 2003;312:1159–64.
10.
FieldingBC. Human coronavirus NL63: a clinically important virus?Future Microbiol. 2011;6:153–9.
11.
WuKLiWPengGLiF. Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor. Proceed Nat Acad Sci. 2009;106:19970–4.
12.
GallagherTM. Murine coronavirus spike glycoprotein. Receptor binding and membrane fusion activities. Adv Exp Med Biol. 2001;494:183–92.
13.
ChenYGuoYPanYZhaoZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Comm. 2020;525:135–140.
14.
LuRZhaoXLiJ, et al.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.
15.
LanJGeJYuJ, et al.Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020:1–9.
16.
ShangJYeGShiK, et al.Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020:1–8.
17.
HammingITimensWBulthuisMLelyANavisGvan GoorH. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. a first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–7.
18.
ZhouPYangXLWangXG, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.
19.
DonoghueMHsiehFBaronasE, et al.A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:e1–e9.
20.
HarmerDGilbertMBormanRClarkKL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532:107–10.
21.
KuikenTFouchierRASchuttenM, et al.Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263–70.
22.
AckermannMVerledenSEKuehnelM, et al.Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. New Eng J Med. 2020;383(2):120–128.
23.
SimsACBaricRSYountBBurkettSECollinsPLPicklesRJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79:15511–24.
24.
JiaHPLookDCShiL, et al.ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79:14614–21.
25.
WongSHLuiRNSungJJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35:744–748.
26.
ChenLLiXChenMFengYXiongC. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–1100.
27.
WysockiJYeMRodriguezE, et al.Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II–dependent hypertension. Hypertension. 2010;55:90–8.
28.
LiWMooreMJVasilievaN, et al.Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.
29.
KsiazekTGErdmanDGoldsmithCS, et al.A novel coronavirus associated with severe acute respiratory syndrome. New Eng J Med. 2003;348:1953–66.
30.
LeiCFuWQianK, et al.Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. Bio Rxiv. 2020:2020.02.01.929976.
31.
WrappDWangNCorbettKS, et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.
32.
BatlleDWysockiJSatchellK. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?Clin Sci. 2020;134:543–5.
33.
WangPChenJZhengA, et al.Expression cloning of functional receptor used by SARS coronavirus. Biochem Biophys Res Comm. 2004;315:439–44.
34.
BabcockGJEsshakiDJThomasWDAmbrosinoDM. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol. 2004;78:4552–60.
35.
SuiJLiWMurakamiA, et al.Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proceed Nat Acad Sci. 2004;101:2536–41.
36.
GuiMSongWZhouH, et al.Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 2017;27:119–29.
37.
PallesenJWangNCorbettKS, et al.Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceed Nat Acad Sci. 2017;114:E7348–E57.
38.
YuanYCaoDZhangY, et al.Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Comm. 2017;8:15092.
39.
LiFLiWFarzanMHarrisonSC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309:1864–8.
40.
SongWGuiMWangXXiangY. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathogens. 2018;14:e1007236.
41.
LiWZhangCSuiJ, et al.Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005;24:1634–43.
42.
HofmannHGeierMMarziA, et al.Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Comm. 2004;319:1216–21.
43.
LiWSuiJHuangIC, et al.The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology. 2007;367:367–74.
44.
ZhaoYZhaoZWangYZhouYMaYZuoW. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020. doi:10.1101/2020.02.11.20022228
45.
Do NascimentoBJuniorIMarusicA, et al.Novel coronavirus (2019-nCoV) infection in humans: a scoping review and meta-analysis. J Clin Med. 2020;9(4):941.
46.
CaoYLiLFengZ, et al.Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery. 2020;6:1–4.
47.
TaiWHeLZhangX, et al.Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020:17:613–620.
48.
Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145.
49.
YangXYuYXuJ, et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med. 2020;45:475–481.
50.
WallsACParkYJTortoriciMAWallAMcGuireATVeeslerD. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292. e6.
51.
PatelVBZhongJCGrantMBOuditGY. Role of the ACE2/angiotensin 1–7 axis of the renin–angiotensin system in heart failure. Circ Res. 2016;118:1313–26.
52.
PinheiroDSSantosRSJardimPCV, et al.The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: a genetic association study in Brazilian patients. PloS One. 2019;14:e0221248.
53.
LiuCLiYGuanT, et al.ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus. Cardiovasc Diab. 2018;17:127.
54.
SmythLJCañadas-GarreMCappaRCMaxwellAPMcKnightAJ. Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis. BMJ Open. 2019;9:e026777.
55.
XuJSriramulaSXiaH, et al.Clinical relevance and role of neuronal AT1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension. Circ Res. 2017;121:43–55.
56.
FerrarioCMJessupJChappellMC, et al.Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–10.
57.
YangWBaiYXiongY, et al.Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature. 2016;531:651–5.
58.
SolerMJYeMWysockiJWilliamJLloverasJBatlleD. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Phys Renal Physiol. 2009;296:F398–F405.
59.
IshiyamaYGallagherPEAverillDBTallantEABrosnihanKBFerrarioCM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970–6.
60.
KlimasJOlvedyMOchodnicka MackovicovaK, et al.Perinatally administered losartan augments renal ACE 2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015;19:1965–74.
61.
FuruhashiMMoniwaNMitaT, et al.Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by Olmesartan, an angiotensin II receptor blocker. Am J Hype. 2015;28:15–21.
62.
AnguianoLRieraMPascualJSolerM. Circulating ACE2 in cardiovascular and kidney diseases. Curr Med Chem. 2017;24:3231–41.
63.
Ortiz-PerezJTRieraMBoschX, et al.Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS One. 2013;8:e61695.
64.
EslerMEslerD. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?J Hypertension. 2020;38:781–2.
65.
DanserAJEpsteinMBatlleD. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382–1385.
66.
HuentelmanMJZubcevicJHernandez PradaJA, et al.Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 2004;44:903–6.
67.
TurnerAJHiscoxJAHooperNM. ACE2: from vasopeptidase to SARS virus receptor. Trend Pharm Sci. 2004;25:291–4.
68.
SunMYangJSunYSuG. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E014.
69.
HanffTCHarhayMOBrownTSCohenJBMoharebAM. Is there an association between COVID-19 mortality and the renin-angiotensin system—a call for epidemiologic investigations. Clin Infect Dis. 2020;71(15):870–874.
70.
VaduganathanMVardenyOMichelTMcMurrayJJPfefferMASolomonSD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. New Eng J Med. 2020;382:1653–9.
71.
LiJWangXChenJZhangHDengA. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5(7):1–6.
72.
MehraMRDesaiSSKuySHenryTDPatelAN. Cardiovascular disease, drug therapy, and mortality in COVID-19. New Eng J Med. 2020;382:e102.
73.
ManciaGReaFLudergnaniMApoloneGCorraoG. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. New Eng J Med. 2020;382(25):2431–2440.
74.
ReynoldsHRAdhikariSPulgarinC, et al.Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441–2448.
75.
VerdecchiaPCavalliniCSpanevelloAAngeliF. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14–20.
76.
MagroneTMagroneMJirilloE. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target-a perspective. Endocr Metab Immune Disord Drug Targets. 2020;20(6):807–811.
77.
ImaiYKubaKRaoS, et al.Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–6.
78.
CrackowerMASaraoROuditGY, et al.Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–8.
79.
KubaKImaiYRaoS, et al.A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11:875–9.
80.
PeiróCMoncadaS. Substituting angiotensin-(1-7) to prevent lung damage in SARS-CoV-2 infection?Circulation. 2020;141:1665–6.
81.
ChenQYangYHuangYPanCLiuLQiuH. Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury. J Surg Res. 2013;185:740–7.
82.
VicenziMDi CosolaRRuscicaM, et al.The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. Euro Resp J. 2020;56:2001157. doi:10.1183/13993003.01157-202
83.
TadicMCuspidiCManciaGDell’OroRGrassiG. COVID-19, hypertension and cardiovascular diseases: should we change the therapy?Pharm Res. 2020;158:104906.
84.
KaiHKaiM. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hyper Res. 2020:43:648–654.
85.
BavishiCMaddoxTMMesserliFH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1282
86.
CismaruACismaruLNabaviSF, et al.Game of “crowning” season 8: RAS and reproductive hormones in COVID-19 – can we end this viral series?Arch Med Sci. 2020. doi:10.5114/aoms.2020.96604
87.
RadenkovicDChawlaSPirroMSahebkarABanachM. Cholesterol in relation to COVID-19: should we care about it?J Clin Med. 2020; 9:E1909.
88.
KatsikiNBanachMMikhailidisDP. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch Med Sci. 2020;16:485–489.
